Bahl & Gaynor Inc. Trims Position in Amgen Inc. (NASDAQ:AMGN)

Bahl & Gaynor Inc. trimmed its position in shares of Amgen Inc. (NASDAQ:AMGN) by 25.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 308,715 shares of the medical research company’s stock after selling 105,555 shares during the period. Bahl & Gaynor Inc. owned 0.06% of Amgen worth $80,463,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Capital Performance Advisors LLP purchased a new stake in Amgen during the 3rd quarter valued at approximately $25,000. Legacy Investment Solutions LLC purchased a new position in Amgen during the third quarter valued at $29,000. Centricity Wealth Management LLC purchased a new position in Amgen during the fourth quarter valued at $25,000. Heck Capital Advisors LLC bought a new stake in Amgen in the 4th quarter valued at $36,000. Finally, Kennebec Savings Bank purchased a new stake in Amgen in the 3rd quarter worth $57,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Citigroup reaffirmed a “neutral” rating on shares of Amgen in a research note on Wednesday, February 5th. Deutsche Bank Aktiengesellschaft decreased their price target on shares of Amgen from $305.00 to $285.00 in a research note on Wednesday, November 27th. Truist Financial dropped their price objective on shares of Amgen from $333.00 to $298.00 and set a “hold” rating for the company in a research note on Wednesday, January 8th. William Blair reaffirmed an “outperform” rating on shares of Amgen in a report on Tuesday, November 12th. Finally, Redburn Partners dropped their price target on Amgen from $200.00 to $195.00 in a research report on Wednesday, November 27th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Amgen has an average rating of “Hold” and an average price target of $314.09.

Amgen Trading Up 0.9 %

NASDAQ:AMGN opened at $310.78 on Tuesday. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. The firm has a 50-day simple moving average of $281.80 and a 200-day simple moving average of $299.73. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85. The firm has a market cap of $166.95 billion, a P/E ratio of 41.16, a P/E/G ratio of 2.63 and a beta of 0.56.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, topping analysts’ consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. Equities analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be paid a dividend of $2.38 per share. This is an increase from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a dividend yield of 3.06%. The ex-dividend date of this dividend is Friday, February 14th. Amgen’s payout ratio is presently 126.09%.

Insider Activity

In related news, SVP Nancy A. Grygiel sold 1,589 shares of the company’s stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total value of $483,802.83. Following the sale, the senior vice president now owns 7,210 shares in the company, valued at $2,195,228.70. This represents a 18.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP David M. Reese sold 25,225 shares of the firm’s stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the transaction, the executive vice president now directly owns 36,922 shares of the company’s stock, valued at $11,240,533.68. This represents a 40.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 69,341 shares of company stock valued at $20,644,335 over the last ninety days. 0.69% of the stock is currently owned by insiders.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.